自閉症譜系障礙治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Autism Spectrum Disorder Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月28日 | 出版商:

Global Market Insights Inc. | 英文 231 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球自閉症譜系障礙(ASD) 治療市場估值為341 億美元，預計2024 年至2032 年複合年成長率為4.8%。盛行率的上升，診斷標準的提高、意識的提高和遺傳影響擴大影響疾病。

隨著自閉症譜系障礙意識的提高，越來越多的人接受診斷，刺激了全球對有效治療的需求。例如，美國疾病管制與預防中心 (CDC) 報告稱，美國大約每 54 名兒童中就有 1 名被診斷患有自閉症譜系障礙 (ASD)，這標誌著過去十年診斷率顯著上升。這種診斷激增促進了治療方法的創新，導致行為療法、藥理學解決方案和數位療法的創建，進一步推動市場成長。

診斷工具的進步有助於 ASD 治療產業的發展。隨著這些技術的發展，它們增強了更早檢測 ASD 的能力，從而導致更多的診斷。確診病例的增加擴大了治療需求，推動了市場擴張。此外，醫療保健專業人員和家長意識的提高，加上先進的診斷工具，導致 ASD 篩檢和診斷的增加。這尤其重要，因為它引起了人們對先前診斷不足的病例的關注，拓寬了自閉症譜系障礙治療的市場。

整個產業分為治療類型、疾病、年齡層、最終用途和地區。

市場依治療類型分為藥物、治療和輔助應用。藥物類別包括抗精神病藥物、選擇性血清素再攝取抑制劑、興奮劑等。治療部分包括行為和溝通療法、螯合療法等。 2023年，藥品板塊引領市場，估值達168億美元。這部分對於管理自閉症譜系障礙相關症狀至關重要，包括行為挑戰和溝通問題，以及焦慮等併發病症。

自閉症譜系障礙（ASD）治療市場將疾病分為自閉症、亞斯伯格症、廣泛性發展障礙（PDD）等。 2023 年，自閉症細分市場佔據 52.2% 的主導市場。該細分市場對於滿足自閉症挑戰更嚴重的個人的需求至關重要。這裡的治療結合了行為療法、藥理學方法和支持服務，所有這些都旨在改善生活品質和發育結果。

自閉症譜系障礙治療市場按年齡分為兒童和成人。 2023年，兒童細分市場以253億美元的估值處於領先地位。這種主導地位歸因於認知的提高、及時的診斷以及兒童自閉症譜系障礙盛行率的不斷上升。兒童的治療途徑包括行為療法、溝通策略、教育措施和藥物監督。其中，行為療法，尤其是應用行為分析脫穎而出，強調透過強化技術來提高技能。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Service Provider
Medication Manufacturer

簡介目錄

Product Code: 11087

The Global Autism Spectrum Disorder (ASD) Treatment Market was valued at USD 34.1 billion in 2023 and is projected to grow at a CAGR of 4.8% from 2024 to 2032. Several factors drive this market growth, notably the rising prevalence of ASD, which is increasingly shaped by enhanced diagnostic criteria, growing awareness, and genetic influences.

As awareness of ASD rises, more individuals receive diagnoses, fueling a global demand for effective treatments. For example, the Centers for Disease Control and Prevention (CDC) reports that about 1 in 54 children in the U.S. is diagnosed with ASD, marking a notable uptick in diagnosis rates over the last decade. This diagnostic surge has catalyzed innovations in treatment methods, leading to the creation of behavioral therapies, pharmacological solutions, and digital therapeutics, further propelling market growth.

Advancements in diagnostic tools help in the growth of the ASD treatment industry. As these technologies evolve, they enhance the ability to detect ASD earlier, resulting in more diagnoses. This uptick in diagnosed cases amplifies the demand for treatments, fueling market expansion. Moreover, increased awareness among healthcare professionals and parents, coupled with advanced diagnostic tools, has led to a rise in screenings and diagnoses of ASD. This is especially significant as it brings attention to previously underdiagnosed cases, broadening the market for ASD treatments.

The overall industry is divided into treatment type, disease, age group, end-use, and region.

The market is categorized by treatment type into drugs, therapy, and assistive applications. Within the drugs category, there are antipsychotic drugs, selective serotonin reuptake inhibitors, stimulants, and others. The therapy segment includes behavior and communication therapies, chelation therapy, and more. In 2023, the drugs segment led the market, achieving a valuation of USD 16.8 billion. This segment is vital for managing ASD-related symptoms, including behavioral challenges and communication issues, as well as co-occurring conditions like anxiety.

ASD treatment market categorizes diseases into autistic disorder, Asperger syndrome, pervasive developmental disorder (PDD), and others. In 2023, the autistic disorder segment held a dominant market share of 52.2%. This segment is essential for catering to individuals with more pronounced autism challenges. Treatments here combine behavioral therapies, pharmacological methods, and supportive services, all aimed at improving life quality and developmental results.

Autism spectrum disorder treatment market segments by age into children and adults. In 2023, the children segment led with a valuation of USD 25.3 billion. This dominance is attributed to heightened awareness, timely diagnoses, and a growing prevalence of ASD in children. Treatment avenues for children encompass behavioral therapies, communication strategies, educational initiatives, and medication oversight. Among these, behavioral therapies, especially applied behavior analysis, stand out, emphasizing skill enhancement through reinforcement techniques.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of autism
  - 3.2.1.2 Advancements in diagnostic tools
  - 3.2.1.3 Innovation in therapeutics
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Variability in treatment efficacy
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Drugs
- 5.2.1 Antipsychotic drugs
- 5.2.2 Selective serotonin reuptake inhibitors
- 5.2.3 Stimulants
- 5.2.4 Other drugs
5.3 Therapy
- 5.3.1 Behavior and communication therapies
- 5.3.2 Chelation therapy
- 5.3.3 Other therapies
5.4 Assistive apps

Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Autistic disorder
6.3 Asperger syndrome
6.4 Pervasive developmental disorder (PDD)
6.5 Other diseases

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Children
7.3 Adult

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Homecare settings
8.4 Rehabilitation centers
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Service Provider
- 10.1.1 Autism Research Institute
- 10.1.2 Child Mind Institute, Inc.
- 10.1.3 Cleveland Clinic
- 10.1.4 Mayo Foundation for Medical Education and Research (MFMER).
- 10.1.5 The General Hospital Corporation
10.2 Medication Manufacturer
- 10.2.1 Axial Therapeutics Inc.
- 10.2.2 Bristol - Myers Squibb Company
- 10.2.3 Curemark LLC
- 10.2.4 Eli Lilly and Company
- 10.2.5 F. Hoffmann - La Roche Ltd.
- 10.2.6 Johnson and Johnson Services, Inc.
- 10.2.7 Novartis AG
- 10.2.8 Otsuka Pharmaceutical Co., Ltd.
- 10.2.9 PaxMedica
- 10.2.10 Pfizer Inc